Carbonic Anhydrase Inhibitors of Different Structures Dilate Pre-Contracted Porcine Retinal Arteries

Figures

• 

  Figure 1. Chemical structures of compounds 1–6 used in this study.

• 

  Figure 2. The effects of U-46619, BZA and DZA on wall tension in porcine retinal arteries. A: Continuous myography recording of wall tension in one artery. The vertical arrow on the left indicates the time point when 10−6 M U-46619 was added to the bath. The wall tension then increases and reaches a peak, and 10−3 M BZA was added at the time indicated by the right vertical arrow. Note the rapid vasodilation induced by BZA to the baseline level. B: Myography recording from another artery. After vasoconstriction induced by U-46619 reached a peak, 10−3 M DZA was added at the time indicated by the middle arrow. The left vertical arrow indicates an addition of 10−3 M BZA. Note the additional dilation induced by BZA. C: Mean concentration-response curves for the dilatory effects of BZA (filled circles) and a (open triangles), expressed as a percentage of the maximum contraction induced by U-46619. Symbols represent the mean ± standard error of the mean (SEM) dilation at each concentration. D: The mean ± SEM dilation induced by BZA and DZA in response to a single dose of 10−3 M added to the bathing solution, as a percentage of the maximum contraction induced by U-46619. An asterix (*) above bars…

• 

  Figure 3. The effects of U-46619 and compounds 3 and 4 on retinal arterial wall tension. A: Continuous recording of wall tension. First, 10−6 M U-46619 was added to the bath, and when the vasoconstriction reached a peak in the experiment shown, a single dose of 10−3 M of compound 3 was added at the point indicated by the right vertical arrow. B: Continuous recording of wall tension from another vessel. At the peak of vasoconstriction induced by U-46619, a dose of 10−3 M of compound 4 was added at the point indicated by the right arrow. C: Mean concentration-response curves for the dilatory effects of compounds 3 (filled circles) and 4 (open triangles), expressed as a percentage of U-46619 induced maximum contraction. D: The mean dilation induced by compounds 3 and 4 in response to a single dose of 10−3 M added to the bathing solution, as a percentage of the maximum contraction induced by U-46619. An asterix (*) above a bar indicates statistically significant vasodilation (p < 0.01 and p < 0.002).

• 

  Figure 4. The effects of U-46619, and compounds 5 and 6 on retinal arterial wall tension. A: Continuous recording of wall tension. After adding 10−6 M U-46619 to the bath, and when constriction had reached a peak, a single dose of 10−3 M of compound 5 was added, as indicated by the right vertical arrow. B: Recording of wall tension from a second vessel. At the peak of vasoconstriction induced by U-46619, a dose of 10−3 M of compound 6 was added at the point indicated by the right arrow. C: Mean concentration-response curves for the dilatory effects of compounds 5 (filled circles) and 6 (open triangles), expressed as a percentage of U-46619 induced maximum contraction. D: The mean dilation induced by compounds 5 and 6 in response to a single dose of 10−3 M added to the bathing solution, as a percentage of the maximum contraction induced by U-46619. Asterix (*) above the bars indicate statistically significant vasodilation (p < 0.001 and p < 0.002).